← Back

News

Friday, 16 January 2015

The first H2020 Project with ICN2 as a partner will develop a fast and cheap kit to diagnose Sepsis

The project, led from ICFO and funded with 3€ million by the EC, is entitled "Scalable, point-of-care and label free microarray platform for rapid detection of Sepsis (RAIS)". It will develop a portable microarray platform potentially capable of measuring more than 1 million biotargets. CSIC Prof. Laura M. Lechuga, Group Leader at ICN2, is among the project partners.

Sepsis is a life threatening inflammatory reaction caused by a serious infection. If not treated properly, it could lead to multi-organ failure, shock and death of the patient (50%-70% of the cases). When fast and accurate results are critical, the advances in the field of nanodiagnostics can translate into life changing health outcomes. CSIC Prof Laura M. Lechuga, Group Leader of the ICN2 NanoBiosensors and Bioanalytical Applications Group, is among the partners of Scalable, point-of-care and label free microarray platform for rapid detection of Sepsis (RAIS), the latest European effort to fight sepsis through a fast, accurate and cheap diagnostic kit.

RAIS is a H2020 Project led by Prof. Valerio Pruneri from ICFO and funded by the European Commission with €3 million. It started officially in January 1, 2015, aiming to develop a new point-of-care label-free microarray platform and validate it for quantifying levels of specific Sepsis’ biomarkers. The approach uses a novel interferometric technique ultimately capable of providing very large arrays of tests. It involves 4 research Institutes (ICFO, ICN2, VHIR and EPFL) and 4 companies (microTEC, Trinean, Thermo Fischer Scientific BRAHMS and iXscient). The project will develop an optical microarray reader based on a disruptive proprietary design combining interferometric lensfree microscopy and proximity CCD (charge coupled device) and CMOS (complementary metal oxide semiconductor) image sensing. Everything will be integrated in a portable microarray platform potentially capable of measuring more than 1 million biotargets simultaneously.

The cost per patient should be under 50€, while the estimated cost savings could rise to €10 billion per year as a consequence of shorter hospital stays, reduced use of unnecessary drugs and lower associated insurance bills. The excellence of the research developed at ICN2 and the rest of the partners will contribute to the success of this necessary diagnostic solution.

RAIS is the first H2020 project where the ICN2 is involved as a partner and, thus, a great way to start 2015. The ICN2 Projects Department will coordinate the reporting of the institutional budget of this project where ICN2 is present through Prof. Laura M. Lechuga and CSIC.